Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Living Cell Technologies ( (AU:1AI) ) is now available.
Algorae Pharmaceuticals has announced the receipt of comprehensive in silico synergy predictions from its AI platform, AlgoraeOS v2, which evaluates over 500,000 CBD-drug-cell line combinations. The platform outperforms existing models, including those from Google DeepMind, across major synergy metrics, and has identified 90 high-quality drug combination candidates for further evaluation. The company is in discussions with the Peter MacCallum Cancer Centre for independent validation of these results, marking a significant step in its AI-driven drug discovery efforts.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical company that focuses on drug discovery and development. The company leverages advanced AI models to explore potential drug combinations, particularly involving CBD, across various cell lines. Algorae is actively engaged in collaborations with research institutions to validate and expand its AI-driven discoveries.
YTD Price Performance: 70.0%
Average Trading Volume: 3,510,725
Technical Sentiment Signal: Buy
Current Market Cap: A$25.33M
See more data about 1AI stock on TipRanks’ Stock Analysis page.